Examining the Impact of Darolutamide on Pain and QoL in Patients With Nonmetastatic CRPC


Karim Fizazi, MD, PhD, professor and head of the GARD Inpatient Unit, at Institut Gustave Roussy, discusses the impact of darolutamide (ODM-201) on pain and quality of life in patients with nonmetastatic castration-resistant prostate cancer. 

Related Videos
Related Content